Full-Time
Director of Value-Based Care Partnerships
Updated on 7/21/2026
iRhythm Technologies
1,001-5,000 employees
Wearable cardiac monitoring with data analysis
No salary listed
Remote in USA
Remote
Remote within the United States.
 Business & Strategy (1) |
|---|
Get referred to iRhythm Technologies
Find people who can refer or advise you
- 12+ years of progressive experience in B2B healthcare sales, ideally in value-based care, digital health, or population health.
- Demonstrated success in managing complex, enterprise-level sales cycles and achieving or exceeding multimillion-dollar targets.
- Deep understanding of value-based economics, payer–provider relationships, and clinical–financial outcome alignment.
- Proven ability to engage and influence executive and C-suite stakeholders.
- Exceptional communication, storytelling, and presentation skills, with the ability to distill complex concepts into actionable value narratives.
- Highly organized, detail-oriented, and self-motivated; adept at prioritizing multiple strategic accounts and complex deal structures.
- Willingness to travel up to 30–50% for key client meetings, conferences, and strategic visits.
- Drive Strategic Growth: Own a defined territory and customer portfolio, identifying and closing new opportunities with payers, health systems, and provider organizations engaged in value-based care initiatives.
- Enterprise Account Management: Build, nurture, and expand high-value relationships with existing partners to drive renewals, expansion, and new program launches.
- Executive-Level Engagement: Develop and deliver compelling, data-driven presentations to C-suite leaders and key decision-makers, connecting clinical outcomes to financial value.
- Collaborate Cross-Functionally: Partner with internal stakeholders across Marketing, Product, and Customer Success to shape customized proposals, ensure delivery alignment, and maximize partner satisfaction.
- Pipeline & Forecast Discipline: Maintain accurate pipeline management and forecasting within CRM, balancing near-term execution with long-term strategic opportunity development.
- Thought Leadership & Representation: Serve as a credible voice of iRhythm’s value-based care capabilities in the marketplace, contributing to industry engagement and positioning the company as a trusted partner.
- Virtual & In-Person Influence: Effectively engage prospects through both virtual meetings and in-person visits, leveraging executive presence to build trust and consensus.
- Strategic Seller: Balances creativity and discipline to develop long-term, high-value relationships.
- Trusted Advisor: Builds credibility with executive leaders through insight and follow-through.
- Storyteller: Connects clinical and financial impact through compelling, data-backed narratives.
- Persistent and Purposeful: Combines drive and tenacity with professionalism and integrity.
- Collaborative Partner: Works cross-functionally to design and deliver meaningful client outcomes.
iRhythm Technologies develops cardiac monitoring technology centered on the Zio Patch, a wearable device that records heart rhythms for up to 14 days. The patch is worn by patients to collect continuous heart data, which iRhythm analyzes and interprets to provide diagnostic insights to clinicians without frequent in-person visits. Compared with rivals, the Zio Patch focuses on long-duration, non-intrusive monitoring combined with integrated data analysis that supports telehealth and clinician workflows. Its goal is to improve arrhythmia detection and diagnostic accuracy while streamlining patient care through scalable wearable monitoring and data interpretation.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2006
Get referred to iRhythm Technologies
Find people who can refer or advise you
Simplify's Take
What believers are saying
- Q1 2026 revenue grew 26% year-over-year to $199.4 million, exceeding analyst estimates.
- Serves over 12 million patients globally, creating unmatched proprietary AI dataset for algorithm refinement.
- Zero impact on Zio device systems or patient safety following June 2026 third-party breach.
What critics are saying
- June 2026 breach exposed PHI for 8 million patients, enabling medical identity theft and phishing.
- HHS HIPAA enforcement action imminent due to material PHI breach, triggering fines up to $50K per violation.
- FDA-mandated Zio Patch recall possible if firmware vulnerabilities alter ECG readings, causing $200 million field costs.
What makes iRhythm Technologies unique
- Zio Patch is the smallest, lightest 14-day cardiac arrhythmia diagnostic available.
- Proprietary AI algorithms analyze over two billion hours of heartbeat data from 12 million patients.
- FDA-cleared deep-learned algorithm achieves 99% physician agreement for arrhythmia detection reports.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Mental Health Support
Hybrid Work Options
Pet Insurance
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 1%Cardiac patients' medical data stolen and held to ransom. Cardiac monitoring provider iRhythm has been hit by a data theft followed by an extortion attempt. In a filing with the Securities and Exchange Commission (SEC), iRhythm revealed it was contacted by someone on June 9 who claimed to have stolen sensitive information, including proprietary data, patient PHI, and other personal information. That person demanded payment in exchange for not publishing the data. iRhythm provides ambulatory cardiac monitoring and analysis (for example using the Zio patch) and has reportedly processed over two billion hours of heartbeat data from more than twelve million patients. In the filing, the company said the data was obtained through social engineering and is from "certain third-party-hosted business applications", without revealing any further details about the amount of data. On its own website, iRhythm also doesn't disclose much about the nature of the stolen data, but does seem to imply no financial data was affected: "Malwarebytes Inc. has not identified any impact to its products, its clinical or medical device systems, its connections to customers, its manufacturing and distribution operations, patient safety, or its ability to meet patient needs. In addition, Malwarebytes Inc. do not store or retain individual financial account information or payment card information. As Malwarebytes Inc. actively investigate, Malwarebytes Inc. will notify individuals affected by this incident in accordance with applicable law and take steps as needed to protect and remediate the impact to them." However, the SEC filing adds that iRhythm determined that the incident is significant, "in light of the volume of the potentially affected data." Together with the extortionist's claims that they have patients' medical data, that makes the breach one worth noting if you have used iRhythm's services. Even without payment data, healthcare breaches have serious downstream effects: * Attackers can craft highly convincing emails, texts, or calls that reference specific procedures or monitoring episodes (for example, "about your recent Zio patch recording") to trick patients into sharing more data or paying fake bills. * The breached data can be used to create a fake identity, insurance fraud, or medical identity theft. * Exposure of cardiac and other health-related information can be deeply sensitive and may have employment/insurance ramifications, especially if data is posted publicly or sold to data brokers. Healthcare breach data tends to circulate for years, and victims may face sporadic fraud and phishing attempts long after the headlines fade. How to stay safe. If you've used iRhythm's services, keep an eye on your post, email, and patient portals for official breach notifications from iRhythm or your healthcare provider. In the US, breaches of protected health information that meet certain criteria must be reported to patients and regulators. iRhythm has promised to "notify individuals affected by this incident in accordance with applicable law and take steps as needed to protect and remediate the impact to them." To stay out of the hands of phishers and scammers: * When you receive a communication about the data breach, verify through other channels that it really came from iRhythm. Go directly to iRhythm's official website or patient portal, or call a known phone number to confirm the communication is genuine. * Be extra suspicious of emails or texts that claim to offer compensation, refunds, or other financial consequences related to this incident. * Change passwords for your iRhythm-linked portals and your cardiology or hospital patient portals, especially if you reused those passwords elsewhere. * Log into your health insurer's portal and check claims on a regular basis. * If you see anything suspicious, report it immediately to your insurer and provider and ask them to flag your account for possible identity theft. * Do not provide personal or financial information over the phone just because the caller knows details about you which they may have obtained from the stolen data. Let's face it, an incognito window can only do so much. Breaches, dark web trading, credit fraud. Malwarebytes Identity Theft Protection monitors for all of it, alerts you fast, and comes with identity theft insurance. Malware Intelligence Researcher Was a Microsoft MVP in consumer security for 12 years running. Can speak four languages. Smells of rich mahogany and leather-bound books.
iRhythm Holdings has gained 9% year-to-date, buoyed by strong volume-led growth across channels and expanding presence in primary care. The ambulatory cardiac monitoring company posted 27% year-over-year revenue growth in fourth-quarter 2025, marking its fifth consecutive quarter exceeding 20% growth. The company now serves approximately 40,000 primary care physicians, with over one-third of total volume coming from these settings. Its deep integration with electronic health record systems and investments in AI-powered diagnostics strengthen its competitive position. iRhythm guides for 2026 revenues of $870-880 million, representing 16%-18% growth. However, the Zacks Rank #3 (Hold) company faces challenges from reimbursement pressures, regulatory headwinds and intensifying competition in cardiac monitoring technologies. Shares trade at a market capitalisation of $3.69 billion.
iRhythm Holdings presented data at the American College of Cardiology 2026 Annual Scientific Sessions demonstrating high prevalence of clinically actionable arrhythmias across cardiovascular-kidney-metabolic patient populations using its Zio ambulatory ECG portfolio. Two retrospective analyses found that 48% of patients with chronic kidney disease and 47% of those with both diabetes and CKD had clinically actionable arrhythmias, compared with 35% of patients with neither condition. A separate study showed patients with severe obesity had nearly threefold higher odds of atrial fibrillation detection compared with normal-weight patients. The company also launched iRhythm Academy, a digital education platform for healthcare professionals. Chief Medical Officer Mintu Turakhia delivered the Louis F. Bishop Keynote on scaling AI in cardiology, emphasising the need to integrate AI into clinical workflows.
iRhythm Technologies reported Q4 revenues of $208.9 million, up 27.1% year-on-year and exceeding analysts' expectations by 3.4%. The cardiac monitoring device maker also beat earnings per share estimates, delivering the strongest analyst beat and highest full-year guidance raise among patient monitoring companies. Despite the strong results, iRhythm's shares have fallen 25.7% since reporting, currently trading at $118.09. The decline suggests investor expectations exceeded Wall Street's published projections. The patient monitoring sector overall reported solid Q4 results, with the four tracked companies beating revenue consensus estimates by 1.9% on average. However, next quarter's revenue guidance came in 1.8% below expectations, and share prices have declined an average of 10.5% following earnings announcements.
iRhythm Holdings has appointed Jason Patten to its Board of Directors, effective 12 March 2026. Patten currently serves as Executive Vice President and Head of Enterprise Strategy at UnitedHealth Group, where he leads corporate strategy, strategic partnerships and innovation functions. The appointment comes as iRhythm, a digital healthcare company specialising in disease detection and prevention, seeks to expand from episodic detection to proactive, integrated care. Chairman Abhi Talwalkar said Patten's experience leading strategy at one of the world's largest healthcare organisations will support the company's growth across primary care, AI capabilities and multiple markets. Patten previously held positions including Chief Operating Officer at OptumHealth and worked in financial services at MoneyGram International and Carlson Marketing Group.